What are Moderna's total assets?

Moderna (MRNA) holds $11.5B in total assets, down 9.6% year over year.

How much debt does Moderna have?

Moderna carries $1.3B in total debt against $7.4B of shareholders' equity, a debt-to-equity ratio of 0.18.

How much cash does Moderna have?

Moderna holds $1.9B in cash and equivalents.

Can Moderna cover its short-term obligations?

Its current ratio is 2.41 — current assets exceed current liabilities.

Where does Moderna's balance sheet data come from?

Every line is extracted from Moderna's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Moderna MRNA Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$2.6B+34.6%	$1.93B-34.1%	$2.93B-9.0%	$3.22B-53.1%
Short-term investments	$3.2B-37.2%	$5.1B-10.5%	$5.7B-14.9%	$6.7B+72.6%
Restricted cash	——	——	——	$12M0.0%
Accounts receivable, net	$184M-48.6%	$358M-59.9%	$892M-35.6%	$1.39B-56.4%
Inventories	$490M-6.0%	$521M-73.7%	$1.98B-71.1%	$6.85B+93.3%
Raw materials	$91M+44.4%	$63M-61.3%	$163M-71.7%	$575M-33.9%
Work in process	$29M+11.5%	$26M+73.3%	$15M-92.7%	$205M-39.3%
Finished goods	$33M+17.9%	$28M+16.7%	$24M-85.8%	$169M-27.5%
Prepaid expenses and other current assets	$408M-31.9%	$599M-4.5%	$627M-47.5%	$1.2B+64.1%
Income taxes receivable	$41M+46.4%	$28M—	$0-100%	$187M+713%
Trading assets	$3.2B-37.2%	$5.1B-10.5%	$5.7B-14.9%	$6.7B+72.6%
Accrued investment income	$42M-28.8%	$59M0.0%	$59M-3.3%	$61M+126%
Total current assets	$6.54B-19.2%	$8.1B-21.6%	$10.33B-23.1%	$13.43B-16.4%
Property and equipment, net	$2.13B-2.8%	$2.2B+12.9%	$1.95B-3.6%	$2.02B+62.6%
Accumulated depreciation	$737M+39.8%	$527M+21.7%	$433M-34.2%	$658M+86.9%
Total property and equipment, gross	$2.87B+5.4%	$2.72B+14.5%	$2.38B-11.1%	$2.68B+68.0%
Operating lease right-of-use assets	$719M-5.3%	$759M+6.5%	$713M+489%	$121M-14.8%
Goodwill	$52M0.0%	$52M0.0%	$52M—	$0—
Intangible assets, net	$45M+12.5%	$40M-9.1%	$44M—	$0—
Other non-current assets	$52M+148%	$21M+90.9%	$11M-54.2%	$24M-47.8%
Available-for-sale securities	$2.34B-6.3%	$2.49B-46.7%	$4.68B-43.8%	$8.32B+21.6%
Allowance for credit losses	$0—	$0—	$0—	$0—
Total assets	$12.34B-12.8%	$14.14B-23.2%	$18.43B-28.7%	$25.86B+4.8%
Accounts payable	$317M-21.7%	$405M-22.1%	$520M+6.8%	$487M+61.3%
Accrued expenses	$420M+90.0%	$221M+71.3%	$129M-48.2%	$249M+10.7%
Deferred revenue	$99M-35.3%	$153M-73.1%	$568M-72.1%	$2.04B-67.4%
Current portion of long-term debt	$25M+8.7%	$23M—	$0-100%	$161M-2.4%
Operating lease liabilities, current	$17M+21.4%	$14M-44.0%	$25M-28.6%	$35M-23.9%
Finance Lease Liability, Current	$25M+8.7%	$23M—	$0-100%	$161M-2.4%
Contract liabilities	$153M+164%	$58M-30.1%	$83M-87.7%	$673M+9.4%
Other current liabilities	$16M-30.4%	$23M-43.9%	$41M-22.6%	$53M+279%
Total current liabilities	$1.99B-9.9%	$2.21B-26.8%	$3.02B-38.8%	$4.92B-46.1%
Long-term debt	$590M—	$0—	——	——
Operating lease liabilities, non-current	$653M-2.7%	$671M+4.4%	$643M+599%	$92M-13.2%
Finance Lease Liabilities (Total)	$45M-27.4%	$62M-89.2%	$575M-46.4%	$1.07B+40.4%
Operating Lease Liabilities (Total)	$670M-2.2%	$685M+2.5%	$668M+426%	$127M-16.4%
Finance lease liabilities	$20M-48.7%	$39M-93.2%	$575M-37.0%	$912M+52.3%
Other non-current liabilities	$285M+6.7%	$267M+4.3%	$256M+89.6%	$135M+77.6%
Total liabilities	$3.69B+13.8%	$3.24B-29.1%	$4.57B-32.1%	$6.74B-36.0%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	1.6B—	0—	0—	0—
Additional paid-in capital	$1.38B+59.6%	$866M+133%	$371M-68.4%	$1.17B-72.1%
Retained earnings	$7.22B-28.1%	$10.05B-26.2%	$13.61B-25.7%	$18.32B+84.0%
Accumulated other comprehensive income (loss)	$45M+550%	-$10M+91.9%	-$123M+66.8%	-$370M-1,442%
Total stockholders' equity	$8.65B-20.6%	$10.9B-21.3%	$13.85B-27.6%	$19.12B+35.2%
Total liabilities and stockholders' equity	$12.34B-12.8%	$14.14B-23.2%	$18.43B-28.7%	$25.86B+4.8%
Available-for-Sale Debt Securities - Amortized Cost	$3.2B-37.3%	$5.11B-11.2%	$5.75B-15.3%	$6.79B+75.0%
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)	$3.2B-37.3%	$5.11B-11.2%	$5.75B-15.3%	$6.79B+75.0%
Available-for-Sale Debt Securities - Fair Value by Maturity	$5.54B-27.0%	$7.59B-26.8%	$10.37B-30.9%	$15.02B+40.0%
Available-for-Sale Debt Securities - Single Maturity Date	$5.54B-27.0%	$7.59B-26.8%	$10.37B-30.9%	$15.02B+40.0%
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	$3M-86.4%	$22M-85.0%	$147M-34.1%	$223M—
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	$3M-86.4%	$22M-85.0%	$147M-34.1%	$223M—
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$1M-83.3%	$6M+50.0%	$4M-98.3%	$241M+363%
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	$1M-83.3%	$6M+50.0%	$4M-98.3%	$241M+363%
Available-for-Sale Debt Securities - Unrealized Loss Position	$1.21B-71.9%	$4.32B-46.1%	$8.01B-39.1%	$13.16B+40.8%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	$3M-86.4%	$22M-85.0%	$147M-34.1%	$223M—
AFS and Trading Securities - Unrealized Loss Position Fair Value	$4M-85.7%	$28M-81.5%	$151M-67.5%	$464M+792%
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$1M-83.3%	$6M+50.0%	$4M-98.3%	$241M+363%
Allowance for Doubtful Accounts	$3M—	$0—	——	——
Allowance for Doubtful Accounts Receivable (Current)	$3M—	$0—	——	——
Cash, Cash Equivalents, and Marketable Securities	$4M-85.7%	$28M-81.5%	$151M-67.5%	$464M+792%
Available For Sale Securities Debt Securities Current	$3.2B-37.2%	$5.1B-10.5%	$5.7B-14.9%	$6.7B+72.6%
Finished goods	$33M+17.9%	$28M+16.7%	$24M-85.8%	$169M-27.5%
Other current assets	$45M+18.4%	$38M-56.8%	$88M+100%	$44M+780%
Prepaid Tax	$37M-17.8%	$45M-10.0%	$50M-64.3%	$140M+100%
Available-for-Sale Debt Securities - Fair Value (Maturing 1 to 5 Years)	$2.33B-6.9%	$2.51B-47.4%	$4.77B-45.1%	$8.69B+26.0%
Deferred Tax Assets and Other Non-Current Assets	$605M+1.9%	$594M-22.5%	$766M-22.5%	$988M+2,048%
Investments - Amortized Cost Basis	$5.53B-27.3%	$7.61B+18,029%	$42M0.0%	$42M—
Net Investment in Lease	$719M-5.3%	$759M+6.5%	$713M+489%	$121M-14.8%
Long-term marketable securities	$2.34B-6.3%	$2.49B-46.7%	$4.68B-43.8%	$8.32B+21.6%
Deferred tax assets	$81M0.0%	$81M0.0%	$81M-91.8%	$982M+201%
Intangible assets — net	$45M+12.5%	$40M-9.1%	$44M—	$0—
Operating lease right-of-use assets	$719M-5.3%	$759M+6.5%	$713M+489%	$121M-14.8%
Other non-current assets	$605M+1.9%	$594M-22.5%	$766M-22.5%	$988M+2,048%
Property, plant and equipment, net	$2.13B-2.8%	$2.2B+12.9%	$1.95B-3.6%	$2.02B+62.6%
Operating Lease Right-of-Use Assets in Other Assets	$719M-5.3%	$759M+6.5%	$713M+489%	$121M-14.8%
Software and Technology Licenses, Net	$605M+1.9%	$594M-22.5%	$766M-22.5%	$988M+2,048%
Accrued Contingent Liabilities	——	——	——	——
Accrued Manufacturing Costs	$420M+34.6%	$312M+27.3%	$245M+28.9%	$190M+50.8%
Accrued Progress Collections and Price Adjustments	$153M+164%	$58M-30.1%	$83M-87.7%	$673M+9.4%
Accrued Royalties (Current)	$31M-32.6%	$46M-62.3%	$122M-39.9%	$203M-15.8%
Other Commercial Liabilities	$1.39B-2.9%	$1.43B-20.6%	$1.8B-14.4%	$2.1B+42.7%
Contract Liabilities and Refund Liability	$509M+37.6%	$370M-33.5%	$556M—	$0—
Accrued Liabilities, Current	$1.39B-2.9%	$1.43B-20.6%	$1.8B-14.4%	$2.1B+42.7%
Compensation and benefits	$420M+34.6%	$312M+27.3%	$245M+28.9%	$190M+50.8%
Other accrued liabilities	$185M-16.3%	$221M+71.3%	$129M-48.2%	$249M+10.7%
Finance Lease Liability Payment Due	——	——	——	——
Finance Lease Liability - Undiscounted Excess Amount	——	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Lease Liability Payments - 2021	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Contract Liabilities, Non-Current	$153M+164%	$58M-30.1%	$83M-87.7%	$673M+9.4%
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Deferred revenue, net of current portion	$153M+164%	$58M-30.1%	$83M-87.7%	$673M+9.4%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	$283M-89.3%	$2.64B-60.2%	$6.64B+20.3%	$5.52B+552,300%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	394M+2.1%	386M+1.0%	382M-0.8%	385M-4.5%
Convertible Preferred Stock Authorized Shares	162M0.0%	162M0.0%	162M0.0%	162M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$0—	$0—	$0—	$0—
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Investments - Gross Unrealized Losses	$4M-85.7%	$28M-81.5%	$151M-67.5%	$464M+792%
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——
Components	108-57.1%	252-35.7%	392-32.6%	582+51.6%
Cumulative Cost Basis	$5.53B-27.3%	$7.61B-27.6%	$10.52B-32.0%	$15.48B+43.7%
Accounts Receivable, Chargebacks, Discounts And Fees	$181M-46.8%	$340M+149%	-$692M—	$0—
Accounts Receivable, after Allowance for Credit Loss	$184M-48.6%	$358M-59.9%	$892M-35.6%	$1.39B—
Clinical trials	$20M-78.7%	$94M-46.3%	$175M-45.1%	$319M+12.7%
Commercial	$23M-48.9%	$45M-19.6%	$56M+16.7%	$48M—
Development operations	$106M-11.7%	$120M-14.3%	$140M+59.1%	$88M-35.8%
Manufacturing	$140M+28.4%	$109M-34.7%	$167M-58.3%	$400M+76.2%
Other external goods and services	$57M-56.5%	$131M-4.4%	$137M-48.1%	$264M+234%
Property, plant and equipment	$45M-54.5%	$99M+5.3%	$94M+1,780%	$5M—
Licensing Arrangements	$31M-32.6%	$46M-62.3%	$122M-39.9%	$203M—
Accounts Receivable, Allowance for Credit Loss	$3M—	$0—	——	——
Total	$5.53B-27.3%	$7.61B-27.6%	$10.52B-32.0%	$15.48B+43.7%
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	$2.33B-6.9%	$2.51B-47.4%	$4.77B-45.1%	$8.69B+26.0%
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	$2.34B-6.3%	$2.49B-46.7%	$4.68B-43.8%	$8.32B+21.6%
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	$3.2B-37.3%	$5.11B-11.2%	$5.75B-15.3%	$6.79B+75.0%
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	$3.2B-37.2%	$5.1B-10.5%	$5.7B-14.9%	$6.7B+72.6%
Collaboration receivable	$13M-77.6%	$58M-4.9%	$61M+455%	$11M—
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$1.6B0.0%	$1.6B0.0%	$1.6B0.0%	$1.6B0.0%
Common stock, shares issued (in shares)	$394M+2.1%	$386M+1.0%	$382M-0.8%	$385M-4.5%
Common Stock, Shares, Outstanding	$394M+2.1%	$386M+1.0%	$382M-0.8%	$385M-4.5%
Contract with Customer, Liability	$252M+19.4%	$211M-67.6%	$651M-76.0%	$2.71B-60.5%
Accrued sales returns	$509M+37.6%	$370M-33.5%	$556M—	$0—
Debt Securities, Available-for-Sale, Allowance for Credit Loss	$0—	$0—	$0—	$0—
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	$283M-89.3%	$2.64B-60.2%	$6.64B+20.3%	$5.52B+552,300%
Less than 12 months	$1M-83.3%	$6M+50.0%	$4M-98.3%	$241M+363%
12 months or more	$3M-86.4%	$22M-85.0%	$147M-34.1%	$223M—
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$931M-44.4%	$1.67B+22.2%	$1.37B-82.1%	$7.64B-18.3%
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss	$1.21B-71.9%	$4.32B-46.1%	$8.01B-39.1%	$13.16B+40.8%
Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions	$108-57.1%	$252-35.7%	$392-32.6%	$582+51.6%
Debt Securities, Available-for-Sale, Unrealized Loss Position	$4M-85.7%	$28M-81.5%	$151M-67.5%	$464M+792%
Deferred income taxes	$249M+7.8%	$231M-1.7%	$235M—	——
Down payments and prepayments, non-current	$100M-28.1%	$139M-59.4%	$342M—	$0—
Unrecognized compensation cost related to non-vested awards	——	——	——	——
Current maturities of long-term debt	$25M+8.7%	$23M—	$0-100%	$161M-2.4%
Finance Lease Liability Payments Due	——	——	——	——
2027	——	——	——	——
Finance Lease Liability Payments Due Year Four	——	——	——	——
Finance Lease Liability Payments Due Year Three	——	——	——	——
Finance Lease Liability Payments Due Year Two	——	——	——	——
Thereafter	——	——	——	——
Finance Lease Liability Undiscounted Excess Amount	——	——	——	——
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$42M-35.4%	$65M-85.1%	$436M-62.1%	$1.15B+72.9%
Research and development funding receivable (Note 5)	$0—	$0—	——	——
Income Taxes Receivable Noncurrent	$161M+66.0%	$97M—	——	——
Interest receivable on interest rate and cross currency swaps	$42M-28.8%	$59M0.0%	$59M-3.3%	$61M+126%
Loss on future firm purchase commitments	$5M-91.7%	$60M-24.1%	$79M-70.5%	$268M—
Lessee Operating Lease Liability Payments Due	——	——	——	——
Thereafter	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Loss Contingency Accrual	——	——	——	——
Number of development candidates	——	——	——	——
Number of development programs	——	——	——	——
Operating And Finance Lease, Liability	$715M-4.3%	$747M-39.9%	$1.24B+3.6%	$1.2B+31.0%
Operating And Finance Lease, Liability, Current	$42M+13.5%	$37M+48.0%	$25M-87.2%	$196M-7.1%
Operating And Finance Lease, Liability, Noncurrent	$673M-5.2%	$710M-41.7%	$1.22B+21.3%	$1B+42.4%
Operating And Finance Lease, Right-Of-Use Asset	$761M-7.6%	$824M-28.3%	$1.15B-9.6%	$1.27B+57.5%
Down payments and prepayments related to manufacturing and materials	$61M-42.5%	$106M-36.9%	$168M-23.3%	$219M-23.7%
Other	$16M-30.4%	$23M-43.9%	$41M-22.6%	$53M+279%
Other	$36M0.0%	$36M+71.4%	$21M—	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$162M0.0%	$162M0.0%	$162M0.0%	$162M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Raw materials	$30M-26.8%	$41M+51.9%	$27M-91.5%	$316M+21.5%
Estimated reimbursements to wholesalers and distributors	$84M-18.4%	$103M—	$0—	——
Research and development funding liability (Note 5)	$43M-25.9%	$58M—	——	——
Remainder of Fiscal Year 2024	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Moderna.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Moderna's total assets?: Moderna (MRNA) holds $11.5B in total assets, down 9.6% year over year.
How much debt does Moderna have?: Moderna carries $1.3B in total debt against $7.4B of shareholders' equity, a debt-to-equity ratio of 0.18.
How much cash does Moderna have?: Moderna holds $1.9B in cash and equivalents.
Can Moderna cover its short-term obligations?: Its current ratio is 2.41 — current assets exceed current liabilities.
Where does Moderna's balance sheet data come from?: Every line is extracted from Moderna's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.